Carregant...
Timing of eculizumab therapy for C3 glomerulonephritis
Eculizumab is an anti-C5 antibody that inhibits C5 cleavage and prevents the generation of the terminal complement complex C5b-9. Eculizumab is licensed to treat paroxysmal nocturnal haemoglobinuria or atypical haemolytic uraemic syndrome (aHUS). Clinical trials are ongoing for C3 glomerulopathy. Gi...
Guardat en:
| Publicat a: | Clin Kidney J |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Oxford University Press
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4515909/ https://ncbi.nlm.nih.gov/pubmed/26251715 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfv065 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|